November 16, 2023 : Inflammatix, a leading innovator in diagnostic solutions for critical care, has announced the completion of technical development for its TriVerity™ Acute Infection and Sepsis Test System. This significant milestone marks a crucial step towards bringing this novel diagnostic tool to market and addressing the critical need for rapid and accurate infection and sepsis detection in clinical settings.
The TriVerity™ Test System utilizes a proprietary host response biomarker platform to quickly identify and differentiate between bacterial, viral, and fungal infections, including bloodstream infections and sepsis. The test provides results within 60 minutes, enabling clinicians to make informed treatment decisions promptly, potentially improving patient outcomes and reducing healthcare costs.
Completing technical development paves the way for Inflammatix to initiate clinical trials for the TriVerity™ Test System. These trials will evaluate the test’s performance in real-world clinical settings, further validating its accuracy and effectiveness in diagnosing acute infections and sepsis.
The successful development of the TriVerity™ Test System represents a significant advancement in critical care diagnostics. The ability to rapidly and accurately identify the cause of infection or sepsis is crucial for optimizing patient care and improving survival rates.
The development of the TriVerity™ Test System addresses a critical unmet need in critical care medicine. Sepsis, a life-threatening condition caused by the body’s overwhelming response to an infection, remains a major global health concern. Early diagnosis and treatment are essential for improving sepsis survival rates, but current diagnostic methods often lack the speed and accuracy required for timely interventions.
The TriVerity™ Test System’s ability to provide rapid and accurate results has the potential to revolutionize sepsis diagnosis and treatment. By enabling clinicians to identify the cause of infection early, the test can facilitate the administration of appropriate antibiotics and other therapies, improving patient outcomes and reducing healthcare costs.
Completing technical development is a significant milestone for Inflammatix, bringing the company closer to commercializing this innovative diagnostic solution. Clinical trials will further validate the test’s performance and pave the way for regulatory approval and widespread adoption in clinical settings.
Inflammatix’s successful completion of technical development for the TriVerity™ Test System marks a significant advancement in the fight against acute infections and sepsis. The test’s ability to provide rapid and accurate results can improve patient outcomes, reduce healthcare costs, and save lives.